Search research articles
Contact Us
Filters
Showing results (1-10 of 9) with videos related to
Page
of 1
Sort By:
Future Oncology (London, England)
|
January 18, 2023
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Urologia Internationalis
|
October 26, 2021
Optimal Treatment for Patients with Oligometastatic Prostate Cancer
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Future Oncology (London, England)
|
February 9, 2022
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Critical Reviews in Oncology/Hematology
|
October 15, 2020
The DNA damaging revolution
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Current Treatment Options in Oncology
|
March 22, 2022
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Immunotherapy
|
June 9, 2023
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Breast Cancer Research and Treatment
|
October 10, 2023
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer
Ozge Gumusay, Laura A Huppert, Mark Jesus M Magbanua, et al.
The Oncologist
|
April 11, 2025
A scoping review of clinical communication in cancer care in Africa
Rebecca J DeBoer, Chiara A Wabl, Beatrice P Mushi, et al.
Science Advances
|
February 4, 2021
A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood
Dianna L Ng, Andrea C Granados, Yale A Santos, et al.
Page
of 1
Search research articles
Search
Showing results (1-10 of 9) with videos related to
Sort By:
Page
of 1
Future Oncology (London, England)
|
January 18, 2023
Should one use the combination of abiraterone and poly(ADP-ribose) polymerase inhibitors as first-line therapy for all patients with metastatic castration-resistant prostate cancer?
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Urologia Internationalis
|
October 26, 2021
Optimal Treatment for Patients with Oligometastatic Prostate Cancer
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Future Oncology (London, England)
|
February 9, 2022
CDK4/6 inhibitors: mechanisms of resistance and potential biomarkers of responsiveness in breast cancer
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Critical Reviews in Oncology/Hematology
|
October 15, 2020
The DNA damaging revolution
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Current Treatment Options in Oncology
|
March 22, 2022
Reshaping Treatment Paradigms for Advanced Renal Cell Cancer Patients and Improving Patient Management : Optimal Management for Renal Cell Cancer Patients
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Immunotherapy
|
June 9, 2023
Advancing immunotherapy in gastroesophageal cancer through rational combinations and biomarkers
Bulent Cetin, Chiara A Wabl, Ozge Gumusay
Breast Cancer Research and Treatment
|
October 10, 2023
A phase Ib/II study of eribulin in combination with cyclophosphamide in patients with advanced breast cancer
Ozge Gumusay, Laura A Huppert, Mark Jesus M Magbanua, et al.
The Oncologist
|
April 11, 2025
A scoping review of clinical communication in cancer care in Africa
Rebecca J DeBoer, Chiara A Wabl, Beatrice P Mushi, et al.
Science Advances
|
February 4, 2021
A diagnostic host response biosignature for COVID-19 from RNA profiling of nasal swabs and blood
Dianna L Ng, Andrea C Granados, Yale A Santos, et al.
Page
of 1